Tivumecirnon (FLX475) is a selective, orally active CCR4 antagonist that blocks the recruitment of immunosuppressive regulatory T cells (Tregs) into the tumor microenvironment, thereby enhancing antitumor immunity. It exhibits antitumor activity against EBV+ NK/T-cell lymphoma and demonstrates antitumor efficacy in combination with pembrolizumab (HY-P9902) in non-small cell lung cancer (NSCLC). Tivumecirnon holds promise for research in a broad range of tumor types.